Symetis' second-gen TAVI device shows positive trial results

04/5/2013 | MassDevice.com (Boston)

Symetis' Acurate TA device, a second-generation transcatheter aortic valve implant already approved in Europe, showed a 98% rate of procedural success and minimal valve leakage in a 250-patient clinical study. The device also showed a 6.8% all-cause mortality rate at 30 days, which the company said was one of the lowest rates reported for TAVI devices.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA